Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04607421
Title BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications

colorectal cancer

Therapies

Bevacizumab + Capecitabine + Oxaliplatin

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Cetuximab + Encorafenib

Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin

Age Groups: senior | child | adult
Covered Countries USA

Additional content available in CKB BOOST